Arcus Biosciences (RCUS) FY2023 results: revenue $117 million, up 4.5% on the year
Arcus Biosciences, Inc. (RCUS) reported revenue of $117 million for fiscal 2023, the year ended 31 December 2023, up 4.5% on the year before. Net income was -$307 million, and diluted earnings per share $-4.15. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2025.
Revenue
$117 million
+4.5% on the year
FY2017FY2023
Operating margin
-290.6%
-250.0% a year earlier
FY2017FY2023
Net income
-$307 million
FY2017FY2023
Diluted EPS
-$4.15
FY2017FY2023
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Operating cash flow
-306
438
-256
Capital expenditure
24.0
6.0
26.0
+300.0%
Free cash flow
-330
432
-282
Free cash flow margin
-282.1%
385.7%
-73.7%
Cash from investing
194
-413
-4.0
Cash from financing
33.0
33.0
237
0.0%
Depreciation and amortisation
8.0
6.0
4.0
+33.3%
Share-based compensation
73.0
65.0
55.0
+12.3%
Diluted shares, weighted
74m
72m
74m
+2.8%
Shares outstanding at period end
76m
73m
71m
+3.6%
Balance sheet
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Shareholders' equity
462
657
841
-29.7%
Debt
0.0
0.0
0.0
Operating lease liabilities
110
117
117
-6.0%
Other liabilities
523
571
634
-8.4%
Total liabilities and equity
1,095
1,345
1,592
-18.6%
Fixed assets
51.0
35.0
32.0
+45.7%
Investments
739
932
533
-20.7%
Cash and equivalents
127
206
148
-38.3%
Other assets
178
172
879
+3.5%
Total assets
1,095
1,345
1,592
-18.6%
10-K for the year ended 31 December 2023, filed 25 February 2025: the filing.